Revolutionary therapeutic treatment for stopping progression of Parkinson's disease

Parkinson's disease (PD) is a common neurodegenerative disorder, affecting over 10 million people worldwide, whereof 1.2 million in the EU. This chronic disabling disease affects the central nervous system, causing severe motor and non-motor symptoms.

The high disease burden for patients and their family also comes with a big price tag for society, which is expected to increase dramatically with an ageing population. In EU the annual cost is 14 B€ currently.

The causes of PD are unknown and there is a broad spectrum of pathologies that ultimately lead to the loss of dopamine producing neurons in the brain.

The current dopamine substitution treatments alleviate some of the symptoms, however, there is no cure for PD nor any disease-modifying therapies.

Herantis has developed a new pharmaceutical HER-096 with the ability to affect PD pathology and potential to revolutionise the treatment of PD, thus alleviating the huge burden it now causes patients and healthcare.